We are live on ! Find out more
MVM

Medicxi Ventures Management Portfolio holdings

AUM $177M
1-Year Est. Return 212.06%
This Fund
S&P 500
This Quarter Est. Return
+44.42%
1 Year Est. Return
+212.06%
3 Year Est. Return
+504.78%
5 Year Est. Return
+412.43%
10 Year Est. Return
–
AUM
$982M
AUM Growth
+$147M
Cap. Flow
-$101M
Cap. Flow %
-10.29%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RAPT
RAPT Therapeutics
RAPT
+$94.6M
2
NAMS icon
NewAmsterdam Pharma
NAMS
+$6.36M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTA
1
DELISTED
Centessa Pharmaceuticals
CNTA
$793M 80.76%
19,963,157
– –
NAMS icon
2
NewAmsterdam Pharma
NAMS
$3.3B
$85.6M 8.72%
2,674,182
-195,383
-7% -$6.36M
PHAT icon
3
Phathom Pharmaceuticals
PHAT
$688M
$82.9M 8.45%
7,464,572
– –
AURA icon
4
Aura Biosciences
AURA
$832M
$20.3M 2.07%
3,039,892
– –
RAPT
5
DELISTED
RAPT Therapeutics
RAPT
– –
-2,794,000
Closed -$94.6M

Similar funds

ACM
Ararat Capital Management Westport, Connecticut $178M AUM 26.61% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return
NRWA
North Ridge Wealth Advisors Beaverton, Oregon $178M AUM 12.81% 1-Year Est. Return
SMTF
Sphera Management Technology Funds Tel Aviv, Israel $178M AUM 42.1% 1-Year Est. Return
AGC
Alden Global Capital Brandon, Florida $177M AUM 32.31% 1-Year Est. Return
CTC
Cetera Trust Company St. Paul, Minnesota $177M AUM 28.75% 1-Year Est. Return
PS
Presima Securities Montreal, Quebec, Canada $178M AUM 1.26% 1-Year Est. Return
XWL
XXI Wealth LLC Chicago, Illinois $177M AUM

Medicxi Ventures Management's Q1 2026 Portfolio in Review

As of Q1 2026, Medicxi Ventures Management held 5 positions worth $982M, up 18% from $835M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Medicxi Ventures Management withdrew a net $101M in Q1 2026, closing 1 position and reducing 1 holding. Its most notable exit was RAPT Therapeutics, an estimated $94.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Medicxi Ventures Management's biggest Q1 2026 reduction was NewAmsterdam Pharma, cutting an estimated $6.36M.
  • Medicxi Ventures Management fully exited RAPT Therapeutics in Q1 2026, selling an estimated $94.6M.
  • Medicxi Ventures Management's ten largest holdings make up 100% of its $982M portfolio in Q1 2026.
  • Medicxi Ventures Management opened 0 new positions and closed 1 in Q1 2026.
  • Medicxi Ventures Management's portfolio value rose 18% quarter-over-quarter to $982M.

Based on Medicxi Ventures Management's 13F filing for Q1 2026, filed 21 Apr 2026.